19940403
 Medarex Inc.   The Wall Street Journal,  Apr 4, 1994  Medarex Inc has signed a letter of intent to develop bispecific antibodies for certain cancer treatments with E. Merck of Germany. E. Merck will provide as much as $29 million to Medarex during the development and clinical trial stages.   
